B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized, single site Phase I study to test the manufacturing
feasibility and safety of locoregional (LR) administration of B7-H3CART into the central
nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose
escalation design.